The exhibit shows the treatment costs, additional health care spending and cost per additional life year associated with ten promising medical innovations. Treatment costs refer to the costs of providing the listed breakthrough technology and are based on comparisons with existing technologies as identified by expert panels. Costs per additional life year do not include improvements in morbidity and disability during a Irfeti me and hence should be thought of as upper bounds on a cost-effectiveness ratio.